Down-regulation of lncRNA Linc00152 suppressed cell viability, invasion, migration, and epithelial to mesenchymal transition, and reversed chemo-resistance in breast cancer cells.

OBJECTIVE Breast cancer is one of the most common cancer types in women, and long non-coding RNAs (lncRNAs) were found to play important roles in breast cancer progression. The present study examined the effects of Linc00152 on the breast cancer progression and explored the underlying molecular mechanisms. MATERIALS AND METHODS The expression levels of relevant genes in tissues and cells were detected by quantitative Real-time PCR (qRT-PCR) assay. Cell viability, growth, invasion, and migration were measured by CCK-8, colony formation, transwell invasion, and migration assays, respectively. Western blot was used to detect the expression levels of proteins. RESULTS The results showed that Linc00152 was highly expressed in the breast cancer tissues compared to their adjacent normal tissues, and Linc00152 was also up-regulated in the breast cancer cell lines compared to normal cell lines. Knock-down of Linc00152 by using siRNAs in breast cancer cell lines (MDA-MB-231 and MCF-7) significantly suppressed cell viability, cell growth, cell invasion and migration as measured by the CCK-8, colony formation, transwell invasion, and migration assays. The qRT-PCR and Western blot results showed that knock-down of Linc00152 suppressed epithelial-mesenchymal transition in breast cancer cell lines. In addition, CCK-8 assay showed that knock-down of Linc00152 in MCF-7/ADR cells reversed the chemo-resistance to doxorubicin. CONCLUSIONS Our results suggested the oncogenic role of Linc00152 in the breast cancer progression. Understanding the role of Linc00152 in breast cancer progression may provide a novel therapeutic target for the treatment of breast cancer.

[1]  Yan Zhang,et al.  lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Y. Zhang,et al.  The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. , 2017, The Journal of clinical investigation.

[3]  Zhonghua Ma,et al.  Long noncoding RNA CRNDE promotes colorectal cancer cell proliferation via epigenetically silencing DUSP5/CDKN1A expression , 2017, Cell Death & Disease.

[4]  N. Zhong,et al.  Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression , 2017, Biology Open.

[5]  Bin Liu,et al.  Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[6]  P. Wei,et al.  Linc00152 promotes Cancer Cell Proliferation and Invasion and Predicts Poor Prognosis in Lung adenocarcinoma , 2017, Journal of Cancer.

[7]  H. Ling,et al.  The "good-cop bad-cop" TGF-beta role in breast cancer modulated by non-coding RNAs. , 2017, Biochimica et biophysica acta. General subjects.

[8]  Baohong Jiang,et al.  Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[9]  Feng Xu,et al.  Long non-coding RNA HOTAIR functions as miRNA sponge to promote the epithelial to mesenchymal transition in esophageal cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  K. Rohr,et al.  The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells , 2017, Scientific Reports.

[11]  Longyang Jin,et al.  Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  Feng Zhu,et al.  Long Noncoding RNA PVT1 Promotes EMT and Cell Proliferation and Migration Through Downregulating p21 in Pancreatic Cancer Cells , 2017, Technology in cancer research & treatment.

[13]  W. Wu,et al.  lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. , 2017, European review for medical and pharmacological sciences.

[14]  Xiang Yu,et al.  Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma , 2017, Cancer medicine.

[15]  Z. Zeng,et al.  Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma , 2017, Journal of Cancer.

[16]  Jun Lu,et al.  The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer , 2016, Cell Death and Differentiation.

[17]  E. Kotteas,et al.  Management and Outcomes in Metaplastic Breast Cancer. , 2016, Clinical breast cancer.

[18]  D. Yan,et al.  Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Yujie Sun,et al.  LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK , 2016, Oncotarget.

[20]  L. Pusztai,et al.  Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. , 2016, The oncologist.

[21]  Maryam Majidinia,et al.  Long non-coding RNAs in cancer drug resistance development. , 2016, DNA repair.

[22]  Shufeng Zhou,et al.  Molecular mechanisms for tumour resistance to chemotherapy , 2016, Clinical and experimental pharmacology & physiology.

[23]  B. Leone,et al.  Adjuvant systemic therapy in older women with breast cancer , 2016, Breast cancer.

[24]  David A Jaffray,et al.  Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition , 2016, The Lancet.

[25]  R. Kong,et al.  Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer , 2016, Oncotarget.

[26]  Zhijin Zhang,et al.  LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. , 2016, American journal of translational research.

[27]  X. Zhi,et al.  Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway , 2015, Journal of Experimental & Clinical Cancer Research.

[28]  B. Han,et al.  The Role of MicroRNAs in the Chemoresistance of Breast Cancer , 2015, Drug development research.

[29]  J. Zhao,et al.  Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer , 2015, Cell cycle.

[30]  T. Xia,et al.  Long noncoding RNA associated-competing endogenous RNAs in gastric cancer , 2014, Scientific Reports.

[31]  S. Zhong,et al.  Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs , 2014, PloS one.

[32]  M. Geng,et al.  A novel long non-coding RNA-ARA: adriamycin resistance-associated. , 2014, Biochemical pharmacology.

[33]  Bangshun He,et al.  Analysis of long non-coding RNA expression profiles in gastric cancer. , 2013, World journal of gastroenterology.